coagulation factor ix (Recombinant) (Rixubis) Report issue

Biologics Recombinant protein Orphan Drug FDA Approved FDA
AACT ChEMBL DrugBank Drug Central

Active Ingredient History

NOW
  • Now
Factor IX is one of the serine proteases of the coagulation system; it belongs to peptidase family S1. Deficiency of this protein causes haemophilia B. It was discovered in 1952 after a young boy named Stephen Christmas was found to be lacking this exact factor, leading to haemophilia.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

bax326 | benefix | coagulation factor ix (recombinant) | coagulation factor ix recombinant human | factor ix (recombinant) | ib1001 | nonacog alfa | nonacog gamma | recombinant coagulation factor ix | recombinant factor ix | rixubis | trenonacog alfa

Organizations (17)

Research & Development (14)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (2)

Approved Indications (1)


 

Hemophilia B (approved 1997)

Experimental Indications - Clinical Trial Phases 1-4 (2)


 

Hemophilia A (Phase 3)

Hemophilia B (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 25
  • # of Trial Organizations: 14

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue